PathogenDx wins NIH grant to expand COVID-19 testing

By staff writers

July 29, 2020 -- PathogenDx has been awarded a grant from the U.S. National Institutes of Health (NIH) to support expansion of its DetectX-Rv COVID-19 microarray assay to a national level.

The grant was provided under the NIH's Rapid Acceleration of Diagnostics (RADx) program for DetectX-Rv, a multiplex viral diagnostic assay that detects COVID-19, as well as COVID-like viruses and subsequent mutations from SARS-CoV-2, according to the firm. The multiplex system will enable thousands of samples to be tested each day, PathogenDx said.

The test is under consideration for an emergency use authorization from the U.S. Food and Drug Administration, according to the company.

PathogenDx partners with Bertin Instruments on airborne COVID-19 test
PathogenDx has formed a partnership with Bertin Instruments to offer a test for airborne contaminants such as SARS-CoV-2 and other airborne viruses.
Nationwide Laboratory Services, PathogenDx team on fungal test
Nationwide Laboratory Services is set to create a laboratory-developed test using the DNA-based platform of PathogenDx, with the aim of offering fungal...

Copyright © 2020

Last Updated eh 7/29/2020 4:33:24 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current